Albireo Current Ratio

Delisted . USA . 
Stock . Albireo Pharma
ALBODelisted Stock  USD 44.15  0.75  1.67%   
Albireo Pharma fundamentals help investors to digest information that contributes to Albireo Pharma's financial success or failures. It also enables traders to predict the movement of Albireo Stock. The fundamental analysis module provides a way to measure Albireo Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Albireo Pharma stock.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  
As of 22nd of March 2023, Current Ratio is likely to grow to 6.73.

Albireo Current Ratio Analysis

Albireo Pharma's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

Albireo Pharma Current Ratio

6.73

Current Ratio 
 = 
Current Asset 
Current Liabilities 
More About Current Ratio | All Equity Analysis

Current Albireo Pharma Current Ratio

    
  4.49 X  
Most of Albireo Pharma's fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Albireo Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Albireo Current Ratio Driver Correlations

Understanding the fundamental principles of building solid financial models for Albireo Pharma is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Current Ratio. Since Albireo Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Albireo Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Albireo Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals

Albireo Current Ratio Historical Pattern

Today, most investors in Albireo Pharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Albireo Pharma's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current ratio growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Albireo Pharma current ratio as a starting point in their analysis.
   Albireo Pharma Current Ratio   
       Timeline  
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Competition

Albireo Net Cash Flow from Operations

Net Cash Flow from Operations

(99.35 Million)

Albireo Pharma Net Cash Flow from Operations is very stable at the moment as compared to the past year. Albireo Pharma reported last year Net Cash Flow from Operations of (96.8 Million)
In accordance with the recently published financial statements, Albireo Pharma has a Current Ratio of 4.49 times. This is 54.3% higher than that of the Biotechnology sector and 35.86% lower than that of the Health Care industry. The current ratio for all United States stocks is 107.87% lower than that of the firm.

Albireo Current Ratio Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Albireo Pharma's direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Albireo Pharma could also be used in its relative valuation, which is a method of valuing Albireo Pharma by comparing valuation metrics of similar companies.
Albireo Pharma is currently under evaluation in current ratio category among related companies.

Albireo Pharma Current Valuation Drivers

We derive many important indicators used in calculating different scores of Albireo Pharma from analyzing Albireo Pharma's financial statements. These drivers represent accounts that assess Albireo Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Albireo Pharma's important valuation drivers and their relationship over time.
201820192020202120222023 (projected)
Net Income Per Employee(1.18 M)(1.14 M)(1.19 M)(261.77 K)(301.03 K)(324.8 K)
Revenue Per Employee326.67 K175.2 K92.06 K312.15 K358.97 K360.48 K
Average Assets199.19 M172.87 M240.71 M266.95 M307 M331.23 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(41.21 M)(57.29 M)(96.08 M)(19.82 M)(17.84 M)(19.25 M)
Earnings Before Interest Taxes and Depreciation Amortization USD(41.21 M)(57.29 M)(96.08 M)(19.82 M)(17.84 M)(19.25 M)
Earnings before Tax(46.09 M)(62.72 M)(107.63 M)(34.03 M)(30.63 M)(33.04 M)
Average Equity142.23 M105.98 M148.89 M154.69 M177.89 M191.93 M
Enterprise Value120.02 M179.83 M446.4 M196.32 M225.76 M188.69 M
Free Cash Flow(26.85 M)(53.46 M)(101.11 M)(108.02 M)(97.22 M)(99.78 M)
Invested Capital(8.5 M)(2.96 M)1.41 M1.34 M1.54 M1.66 M
Invested Capital Average(5.73 M)(3.27 M)2.73 M(872 K)(784.8 K)(846.76 K)
Market Capitalization293.62 M322.49 M715.59 M449 M516.35 M557.11 M
Tangible Asset Value168.21 M147.81 M268.35 M284.79 M327.51 M353.37 M
Working Capital154.82 M122.88 M236.58 M223.58 M257.12 M277.42 M

Albireo Fundamentals

Return On Equity(0.93) %
Return On Asset(0.25) %
Profit Margin(2.29) %
Operating Margin(2.15) %
Current Valuation259.98 M
Shares Outstanding20.74 M
Shares Owned by Insiders3.60 %
Shares Owned by Institutions96.40 %
Number of Shares Shorted553.91 K
Price to Earning(4.16) X
Price to Book4.30 X
Price to Sales7.35 X
Revenue40.58 M
Gross Profit39.22 M
EBITDA(19.82 M)
Net Income(34.03 M)
Cash and Equivalents180.97 M
Cash per Share9.23 X
Total Debt10 M
Debt to Equity0.18 %
Current Ratio4.49 X
Book Value Per Share4.84 X
Cash Flow from Operations(107.56 M)
Short Ratio0.86 X
Earnings Per Share(6.66) X
Target Price44.0
Number of Employees130
Beta1.04
Market Capitalization915.89 M
Total Asset302.05 M
Retained Earnings(171.75 M)
Working Capital26.76 M
Current Asset28.84 M
Current Liabilities2.07 M
Z Score54.6
Net Asset302.05 M

About Albireo Pharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Albireo Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Albireo Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Albireo Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2023
Current Ratio 5.34  6.73 

Be your own money manager

Our tools can tell you how much better you can do entering a position in Albireo Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Share Portfolio Now

   

Share Portfolio

Track or share privately all of your investments from the convenience of any device
All  Next Launch Module

Pair Trading with Albireo Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Albireo Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Albireo Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving against Albireo Pharma

-0.87ABIOARCA Biopharma Fiscal Quarter End 31st of March 2023 PairCorr
-0.71ACERAcer Therapeutics Financial Report 15th of May 2023 PairCorr
-0.59AADIAadi Bioscience Earnings Call This WeekPairCorr
-0.54ACGNAceragen Earnings Call This WeekPairCorr
The ability to find closely correlated positions to Albireo Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Albireo Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Albireo Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Albireo Pharma to buy it.
The correlation of Albireo Pharma is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Albireo Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Albireo Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Albireo Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Please continue to Trending Equities. Note that the Albireo Pharma information on this page should be used as a complementary analysis to other Albireo Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Other Consideration for investing in Albireo Stock

If you are still planning to invest in Albireo Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Albireo Pharma's history and understand the potential risks before investing.
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Equity Valuation
Check real value of public entities based on technical and fundamental data
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets


 
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2023 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY